Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
17 hedge funds and large institutions have $31.5M invested in Bellerophon Therapeutics, Inc. in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 6 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
44% more capital invested
Capital invested by funds: $21.8M → $31.5M (+$9.68M)
21.06% more ownership
Funds ownership: 46.53% → 67.59% (+21%)
15% less funds holding
Funds holding: 20 → 17 (-3)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMVA
New Mountain Vantage Advisers
New York
|
+$5.65M |
| 2 |
VMI
VHCP Management II
New York
|
+$5.14M |
| 3 |
Renaissance Technologies
New York
|
+$151K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$24.7K |
| 5 |
BlackRock
New York
|
+$16.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.32M |
| 2 |
SIM
Spark Investment Management
New York
|
-$91K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$51.4K |
| 4 |
LPL Financial
San Diego,
California
|
-$37.5K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$31K |
BLPH Hedge Fund Activity: Q3 2017 in Review
17 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q3 2017, worth a combined $31.5M — up 44% from $21.8M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BLPH and 5 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 5 added.
The largest buyer was New Mountain Vantage Advisers, adding an estimated $5.65M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $1.32M sold.
- 17 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q3 2017, down from 20 in Q2 2017.
- Funds reported $31.5M of Bellerophon Therapeutics, Inc. stock for Q3 2017, up 44% quarter-over-quarter.
- 5 funds opened new Bellerophon Therapeutics, Inc. positions in Q3 2017 and 6 closed out, a net change of -1 holder.
- The largest Bellerophon Therapeutics, Inc. buyer in Q3 2017 was New Mountain Vantage Advisers, an estimated $5.65M added.
- The largest Bellerophon Therapeutics, Inc. seller in Q3 2017 was Susquehanna International Group, an estimated $1.32M sold.
Based on aggregated 13F filings for Q3 2017.